Sort   by:  
 Page size 
MetabolomicsFetal Metabolic Stress Disrupts Immune Homeostasis and Induces Proinflammatory Responses in Human Immunodeficiency Virus Type 1- and Combination Antiretroviral Therapy-Exposed Infants
Increased morbidity and fetal growth restriction are reported in uninfected children born to human immunodeficiency virus type 1 (HIV-1)–infected women treated with antiretroviral (ARV) therapy. Viruses and/or pharmacological interventions such as ARVs can induce metabolic stress, skewing the cell’s...
2018-06-06 | MTBLS449 | MetaboLights
MetabolomicsCysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis
Nephropathic cystinosis is a severe monogenic kidney disorder caused by mutations in CTNS, encoding the lysosomal transporter cystinosin, resulting in lysosomal cystine accumulation. The sole treatment, cysteamine, slows down the disease progression, but does not correct the established renal proxim...
2021-06-24 | MTBLS2538 | MetaboLights
MetabolomicsOxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...
2023-06-27 | MTBLS3342 | MetaboLights
MetabolomicsRabbit plasma metabolomic analysis of Nitroproston: a multi target natural prostaglandin based-drug (Untargeted study)
INTRODUCTION: Nitroproston® is a novel multi-target drug bearing natural prostaglandin E2 (PGE2) and nitric oxide (NO)-donating fragments for treatment of inflammatory and obstructive diseases (i.e. asthma and obstructive bronchitis). OBJECTIVES: To investigate the effects of Nitroproston® adm...
2019-08-27 | MTBLS727 | MetaboLights
MetabolomicsNiacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Mouse NAMPT targeted therapy)

NAMPT plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi...

2023-10-10 | MTBLS7252 | MetaboLights
MetabolomicsCholesterol metabolism regulates cartilage metabolic-inflammatory crosstalk by triggering osteocyte mitochondria transfer as a therapeutic target for osteoarthritis
Osteoarthritis (OA) is considered as a metabolic related inflammatory disease in the joint affecting both cartilage and subchondral bone. Cholesterol metabolism has been implicated in the pathogenesis of OA, yet the underlying mechanism still remains elusive. Understanding the role of cholesterol me...
2025-09-28 | MTBLS11733 | MetaboLights
MetabolomicsInvestigation of the threonine metabolism of Echinococcus multilocularis: EmTDH as a potential drug target in alveolar echinococcosis
Alveolar echinococcosis is a severe zoonotic disease caused by the fox tapeworm E. multilocularis. New treatment options are urgently needed. Whole-organism-based screening allows the discovery of potential new anti-echinococcal compounds, but suffers from low- to medium-throughput. An alternative a...
2026-09-14 | MTBLS10738 | MetaboLights
MetabolomicsIdentification and validation of a glutamine metabolism-related gene signature as a diagnostic and therapeutic target in osteoarthritis through integrated multi-omics analysis

Identification and validation of a glutamine metabolism-related gene signature as a diagnostic and therapeutic target in osteoarthritis through integrated multi-omics analysis

2025-12-13 | MTBLS13455 | MetaboLights
GenomicsOff-Target Analysis of Zinc Finger Nucleases
Zinc Finger Nucleases (ZFNs) facilitate precise editing of DNA enabling targeted genomic modifications in vivo. ZFNs have been employed to obtain genetically modified plants and animals, and cell-based therapies utilizing ZFNs are undergoing clinical trials. However, many ZFNs display dose-dependent...
ORGANISM(S): Danio rerio 
2010-08-25 | E-GEOD-23762 | biostudies-arrayexpress
MetabolomicsDevelopment of a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var to target glutamine dependency in cancer

The mitochondrial glutamine transporter SLC1A5_var plays a central role in the metabolic reprogramming of cancer cells by facilitating glutamine import into mitochondria for energy production and redox homeostasis. Despite its critical function, the development of effective and selective inhibito...

2025-08-13 | MTBLS12852 | MetaboLights
Sort   by:  
 Page size